RAPGEF3 and lung carcinoma: For patients with TKI resistance and AST, the combination of RAPGEF3 inhibitor and TKI (such as osimertinib + ESI-09) can overcome the resistance mediated by AST, especially in lung cancers with high RAPGEF3 expression.